CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial (UHKT-CAR123-01)
Safety and Efficacy of Anti-CD123 Chimeric Antigen Receptor-Modified Autologous T Cells (CART123) in Patients With Relapsed/Refractory CD123+ Hematologic Malignancies: A Dose Escalation, Open-Label, Phase I Study
Sponsor: Institute of Hematology and Blood Transfusion, Czech Republic
This EARLY_PHASE1 trial investigates Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and Leukemia, Myeloid, Acute(AML) and is currently actively recruiting participants. Institute of Hematology and Blood Transfusion, Czech Republic leads this study, which shows 3 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
3 versions recorded-
Feb 2026 — Present [monthly]
Recruiting EARLY_PHASE1
-
Sep 2025 — Feb 2026 [monthly]
Recruiting EARLY_PHASE1
-
Feb 2025 — Sep 2025 [monthly]
Recruiting EARLY_PHASE1
First recorded
Oct 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Institute of Hematology and Blood Transfusion, Czech Republic
For direct contact, visit the study record on ClinicalTrials.gov .